International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) trimer isolated from individual HIV-infected donors potently neutralize diverse HIV strains, but strategies for designing immunogens to elicit bnAbs have not been identified. Here, we compared four prototypes (PG9, CH01, PGT145, and CAP256.VRC26.09) of V2 apex bnAbs and showed that all recognized a core epitope of basic V2 residues and the glycan-N160. Two prototype bnAbs were derived from VH-germlines that were 99% identical and used a common germline D-gene encoded YYD-motif to interact with the V2-epitope. We identified isolates that were neutralized by inferred germline (iGL) versions of three of the prototype bnAbs. Soluble E...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typic...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Summary Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)...
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natur...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
Summary Recent efforts toward HIV vaccine development include the design of immunogens that can enga...
Broadly neutralizing antibodies (bnAbs) to the HIV envelope (Env) V2-apex region are important leads...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typic...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
SummaryBroadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) ...
Summary Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)...
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natur...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
Summary Recent efforts toward HIV vaccine development include the design of immunogens that can enga...
Broadly neutralizing antibodies (bnAbs) to the HIV envelope (Env) V2-apex region are important leads...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typic...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...